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SUMMARY
While oral polio vaccine (OPV) has been shown to be safe and effective, it has been observed that
it can circulate within a susceptible population and revert to a virulent form. Inactivated polio
vaccine (IPV) confers protection from paralytic disease, but provides limited protection against
infection. It is possible, then, that an IPV-immunized population, when exposed to OPV, could
sustain undetected circulation of vaccine-derived poliovirus. This study examines the possibility
of polio vaccine virus circulating within the United States (highly IPV-immunized) population
that borders Mexico (OPV-immunized). A total of 653 stool and 20 sewage samples collected on
the US side of the border were tested for the presence of poliovirus. All samples were found to be
negative. These results suggest that the risk of circulating vaccine-derived poliovirus is low in fully
immunized IPV-using populations in developed countries that border OPV-using populations.
In 1988 the World Health Assembly passed a resol-
ution committing to the global eradication of polio.
At the time of this resolution, around 350000 cases
occurred annually in 126 countries. Today, polio
is endemic in only four countries and newly re-
introduced in 21 more, with 1831 cases occurring in
2005. As we near the goal of eradication, attention is
increasingly directed toward post-eradication issues.
One such issue is how to discontinue the use of oral
polio vaccine (OPV).
OPV has proven to be safe and effective and has
been the main tool in the eradication effort. One of its
advantages is the ability to be transmitted from re-
cipients, thus providing a boost in immunity to con-
tacts of vaccine recipients. In a very small percentage
of cases, however, OPV can result in vaccine-
associated paralytic poliomyelitis (VAPP). As a
country eliminates wild poliovirus and continues to
use OPV, VAPP makes up a higher proportion of
paralytic polio cases. Because of this risk of VAPP,
many developed countries that have eliminated polio
transmission have switched to using inactivated
polio vaccine (IPV), which does not cause VAPP. The
United States introduced a sequential immunization
schedule of both OPV and IPV in 1997, and switched
to the exclusive use of IPV in 2000.
It is well known that OPV reverts to a more virulent
form with replication. To date, circulating vaccine-
derived poliovirus (cVDPV) has been responsible
for seven outbreaks of poliomyelitis. In addition, in-
stances of single cases or poliovirus-positive sewage
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samples have been found in which the poliovirus has
o1% genetic divergence from the parent Sabin virus
strain in the VP1 region of the viral genome (the
definition of VDPV) [1, 2], consistent with about
1 year or more of viral replication. In all cases, the
outbreaks occurred in populations in which a large
number of susceptible persons had built up because of
gaps in immunization.
IPV provides good protection against disease, but
does not confer complete protection against infection.
Early studies showed that both wild-type and vaccine
poliovirus are easily transmitted from an infected
person to IPV-immunized persons in a household
setting [3]. IPV was also found to offer minimal
protection against infection following a challenge
dose with OPV [4]. Under conditions of community
exposure, where contact with an infected person is not
as close, IPV was shown to confer some protection
against poliovirus infection [3, 5].
Because of suboptimal antibody response to IPV,
by the late 1980s the original IPV was replaced by an
enhanced formulation with increased potency. At the
time the enhanced IPV was introduced, it was only in
use in some western European countries that had
already eliminated wild poliovirus. Studies were done
in which recipients were given a challenge dose
of monovalent OPV to test enhanced IPV’s ability to
protect against infection [6]. These studies showed
that the enhanced IPV conferred less protection
against infection than OPV, but it is difficult to
determine how the virus titre of the challenge dose
compares with the amount of virus that would be
encountered in a natural exposure.
Because IPV confers limited protection against
infection, the possibility exists for wild or vaccine
poliovirus to circulate undetected in persons with
IPV-induced immunity. If vaccine virus circulates
among an IPV-immunized population, the potential
would exist for it to accumulate mutations and
become a virulent cVDPV. The risk for vaccine virus
circulation and the development of virulent VDPVs
should be greatest in situations in which an IPV-
immunized population has extensive contact with an
OPV-immunized population, raising the possibility
that IPV-immunized children could become infected
with vaccine virus from children who had recently
received OPV. In this study we determine whether
vaccine virus (OPV or VDPV) is circulating among
fully IPV-immunized persons (three or more IPV
doses) in the United States where it borders the
OPV-immunized population of Mexico.
Enrolment took place in Cameron and Hidalgo
counties of Texas, which lie along the border with
Mexico in the southernmost part of the state.
Communities in this area are 85–90% Hispanic.
Many have family contacts in Mexico and cross-
border travel is extensive. IPV coverage in these
counties is over 90%. OPV coverage in the Mexican
state of Tamaulipas, which borders the study coun-
ties, is also over 90%.
Because the purpose of this study was to assess
transmission to or among children who had acquired
immunity through IPV vaccination, we restricted
enrolment to those who had received at least three
IPV doses to maximize the number of children with
IPV-induced neutralizing antibodies against polio-
virus. Vaccine history was by oral report from a
parent or guardian. Children who were born after
1 January 2000, lived in one of the two study counties,
had received at least three doses of IPV, and had
never received OPV were enrolled in the study from 12
public and private clinics in Hidalgo and Cameron
counties of Texas. These clinics were chosen because
of accessibility of the patient population. Most are
Women with Infant Children clinics, a public assist-
ance programme, and serve a lower socioeconomic
level population. The parent or guardian of the child
was approached in the clinic by a study interviewer
who explained the study in English or Spanish,
determined eligibility, and obtained consent. Children
were selected for enrolment by a convenience sample.
This study was approved by the institutional review
boards of the Centers for Disease Control and
Prevention and the Texas Department of State Health
Services (TDSHS).
The parent or guardian of each enrolled child was
given instructions on collecting a stool specimen and
given a collection kit. The samples were to be kept
refrigerated until returned to the interviewer. The
interviewer transported the samples in a cooler to the
TDSHS regional office where they were stored at
x70 xC until being shipped on dry ice to the TDSHS
laboratory for testing.
Twenty sewage samples were collected from 17 sites
in the study area during the third week of September,
1 year prior to the collection of the stool samples.
These sites were selected to provide adequate cover-
age of the main population areas covered in the two
study counties. Included in the sites were the sewage
systems covering the clinics from which the study
participants were recruited. Each sample was col-
lected at the main inlet to the community sewage
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treatment plant. The 1-litre samples were stored at
x20 xC before being transported on dry ice to the
University of North Carolina School of Public Health
for testing.
Stool samples were processed using the following
procedure. A stool aliquot was added to 6 ml of
Hank’s Balanced Salt Solution (BSS). The specimen
was vortexed, centrifuged for 20 minutes at 1500 g in
a refrigerated centrifuge, and then the supernatant
transferred to a glass tube. A garamycin/amphotericin
B solution was added to the specimen giving a final
concentration of 100 mg of garamycin and 10 mg of
amphotericin B per millilitre of specimen. The sample
was incubated at 4 xC for 1 h and then inoculated
onto cell cultures. Isolation procedures were then
followed according to the WHO Polio Laboratory
Manual [7]. Sewage samples were processed and tested
using procedures described elsewhere [8].
A total of 664 childrenwere enrolled. Five specimens
were inadvertently discarded and specimens were not
collected from four children. Two additional children
had reported ages inconsistent with the number of re-
ported IPVdoses (2 and 4months) leaving 653 children
for analysis. The median age of the children whose
data were analysed was 26 months, ranging from 6
months to 46 months; 346 (53%) were male. In total,
617 (95%) reported beingHispanic, three (0.5%) non-
Hispanic, two (0.3%) both, and two (0.3%) other.
Twenty-eight (4%) did not report an ethnicity.
All sewage samples tested negative for the presence
of poliovirus while 18 of the 20 (90%) samples tested
positive for non-polio enterovirus. All 653 stool
samples were negative for poliovirus, giving an upper
95% confidence bound for the viral shedding rate of
0.5%. Sixty (9%) children tested positive for non-
polio enterovirus.
The results of the stool and sewage sample tests
indicate that OPV or VDPV is not in widespread
circulation in the fully IPV-immunized population
despite extensive contact between the Mexican and
US populations. The sensitivity of the stool testing to
detect poliovirus is indicated by the ability to detect
non-polio enteroviruses, although the percentage
positive was just under the WHO’s target of 10% for
acute flaccid paralysis surveillance for polio. This
lower rate of non-polio enterovirus infection is not
unusual for a temperate climate. Similarly, non-polio
enterovirus was detected in a high percentage of the
sewage samples, indicating the sensitivity to detect
circulating poliovirus. All samples were collected
during September–October, which is during the peak
of the enterovirus transmission period. It is possible
that some transmission takes place from OPV re-
cipients to IPV recipients or between IPV recipients,
but at a level too low to maintain circulation or to
detect. This finding is consistent with experience in
other IPV-using countries [9].
It is possible that populations in developing
countries with conditions more favourable for polio-
virus circulation may be able to sustain vaccine virus
circulation after switching to IPV. The role of IPV
post-eradication in these countries is unknown at
this time. The main obstacles to using IPV in these
settings, particularly in mass campaigns, are cost and
logistic difficulties. These may change if new dosing
regimens and administration technology such as the
use of fractional doses of IPV and needleless injection
systems prove to be feasible and effective.
This study was designed to investigate OPV or
VDPV transmission among fully IPV-immunized
children. It is possible that transmission may be
taking place at low levels in younger children with
fewer IPV doses or other under-immunized groups,
although this appears unlikely. Moreover, because
OPV coverage is high in Mexico (98% for three
doses of OPV in children aged <1 year in 2004), viral
shedding may be reduced over what would be found
in children with fewer OPV doses, reducing exposure
for the IPV-immunized children.
The results of this study suggest that a developed
country that uses IPV and borders an OPV-using
country may not be at risk for becoming a reservoir
for cVDPV. It is possible that OPV can still be trans-
mitted within pockets of unvaccinated persons within
a vaccinated population. This was illustrated most
recently by the identification of circulating VDPV
in an Amish community in Minnesota [10]. Further
work is needed to determine whether IPV-immunized
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